This amendment (0001) to Solicitation 36E79725R0070, issued by the Department of Veterans Affairs, extends the due date for offers for the Eszopiclone Tablets RFP. The new deadline for receipt of offers is December 2, 2025, at 2:30 PM CST. All other terms and conditions of the original solicitation remain unchanged. Offerors must acknowledge this amendment by signing and submitting it with their offer documents to ensure consideration.
The Department of Veterans Affairs (VA) National Acquisition Center intends to issue an unrestricted Request for Proposal (RFP) 36E79725R0070 for Eszopiclone Tablets. This procurement aims to secure an uninterrupted supply for the VA (including Consolidated Mail Order Pharmacies and State Veterans Homes), Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will span one year with four optional one-year extensions, with items distributed via the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with a unique NDC number and specific packaging requirements, including safety-capped 30-count bottles with a minimum 120cc volume. The solicitation is expected around October 23, 2025, with a tentative closing date of November 6, 2025. The NAICS code for this procurement is 325412. All updates will be posted on SAM.gov, and inquiries should be directed to Richard Mahario at Richard.Mahario@va.gov.
This government solicitation, 36E79725R0070, from the Department of Veterans Affairs, outlines requirements for pharmaceutical prime vendors to supply Eszopiclone tablets. It details the process for offers, including pricing for base and option years, packaging specifications with safety caps and barcoding, and the need for unique 11-digit National Drug Codes (NDCs). The contract, which will be for a base year and four option years, covers all VA, DoD, IHS, and BOP facilities. Key clauses address product registration with FDA and other databases, handling of backorders, drug recalls, and adherence to the Drug Supply Chain Security Act (DSCSA). Offerors must have FDA-approved manufacturing facilities with acceptable cGMP status and will be subject to a 0.5% Cost Recovery Fee on all sales, with mandatory quarterly sales reports.